{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00687","value":"1.0217"},{"groupId":"OG001","spread":"0.00660","value":"1.0253"},{"groupId":"OG002","spread":"0.00946","value":"1.0169"},{"groupId":"OG003","spread":"0.00682","value":"1.0175"},{"groupId":"OG004","spread":"0.00931","value":"1.0217"},{"groupId":"OG005","spread":"0.00544","value":"1.0175"},{"groupId":"OG006","spread":"0.00661","value":"1.0133"},{"groupId":"OG007","spread":"0.00736","value":"1.0167"},{"groupId":"OG008","spread":"0.00612","value":"1.0193"},{"groupId":"OG009","spread":"0.00817","value":"1.0152"},{"groupId":"OG010","spread":"0.00713","value":"1.0174"},{"groupId":"OG011","spread":"0.00627","value":"1.0139"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"12"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"11"},{"groupId":"OG011","value":"14"}],"units":"Participants"}],"title":"Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00058","value":"0.0003"},{"groupId":"OG001","spread":"0.01217","value":"-0.0090"},{"groupId":"OG002","spread":"0.01072","value":"-0.0013"},{"groupId":"OG003","spread":"0.00643","value":"0.0023"},{"groupId":"OG004","spread":"0.00354","value":"0.0075"},{"groupId":"OG005","spread":"0.00671","value":"-0.0020"},{"groupId":"OG006","spread":"0.00707","value":"0.0050"},{"groupId":"OG007","spread":"0.01029","value":"0.0029"},{"groupId":"OG008","spread":"0.00529","value":"-0.0010"},{"groupId":"OG009","spread":"0.00782","value":"0.0005"},{"groupId":"OG010","spread":"0.00792","value":"-0.0026"},{"groupId":"OG011","spread":"0.00830","value":"0.0067"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"13"},{"groupId":"OG010","value":"5"},{"groupId":"OG011","value":"10"}],"units":"Participants"}],"title":"Change from baseline (up to approx. 4.5 years)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"12"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"11"},{"groupId":"OG011","value":"14"}],"units":"Participants"}],"description":"Urine samples were collected to analyze urine specific gravity using dipstick method. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 1.9 milligram (mg)/kilogram (kg) dose on Day 1 of every alternate 28-day cycles (C1, C3, C5, C7 and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide (Len) was administered as 25 mg or 10 mg per oral (PO) on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone (Dex) weekly PO/ intravenously (IV) on Days 1, 8, 15 and 22 of each cycle.","id":"OG000","title":"Main Study Phase: Belantamab Mafodotin 1.9mg/kg STRETCH + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 1.9 mg/kg on Day 1 of every 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG001","title":"Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 2.5mg/kg dose as a 1.25 mg/kg dose on Day 1 and a 1.25 mg/kg dose on Day 8 of each 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG002","title":"Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 2.5 mg/kg on Day 1 of every 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG003","title":"Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of every alternate 21-day cycle (C1, C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib (Bor) was administered as 1.3 milligrams per square meters (mg/m\\^2) subcutaneously (SC) /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone (Dex) PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG004","title":"Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 1.9 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG005","title":"Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on cycle 1 day 1 (C1D1) followed by 1.9 mg/kg step-down dose on Day 1 of every alternate 21-day cycles C3 onwards (C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG006","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on Day 1 of every alternate 21-day cycles (C1, C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG007","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 2.5mg/kg dose as a 1.25 mg/kg on Day 1 and 1.25 mg/kg dose on Day 8 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG008","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 2.5 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG009","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 3.4 mg/kg dose as a 1.7 mg/kg dose on Day 1 and 1.7 mg/kg on Day 8 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG010","title":"Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 3.4 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG011","title":"Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex"}],"paramType":"MEAN","populationDescription":"All treated population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to approximately 4.5 years","title":"Change From Baseline in Urine Specific Gravity","type":"PRIMARY","unitOfMeasure":"Ratio"}